Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538231 | 1.00 | CHRM1 (0.46) | CHRM1HSD17B10ALDH1A1TP53CYP3A4 | |
| SCHEMBL6891371 | 0.89 | HSD17B10 (0.46) | CHRM1HSD17B10ALDH1A1TP53CYP3A4 | |
| SCHEMBL27538415 | 0.89 | HSD17B10 (0.46) | CHRM1HSD17B10ALDH1A1TP53CYP3A4 | |
| SCHEMBL6895946 | 0.89 | HSD17B10 (0.46) | CHRM1HSD17B10ALDH1A1TP53CYP3A4 | |
| SCHEMBL6895691 | 0.87 | HSD17B10 (0.42) | CHRM1HSD17B10ALDH1A1CYP3A4CTSL | |
| SCHEMBL6891320 | 0.87 | HSD17B10 (0.44) | CHRM1HSD17B10ALDH1A1CTSLKDM4E | |
| SCHEMBL6895694 | 0.87 | HSD17B10 (0.42) | CHRM1HSD17B10ALDH1A1CYP3A4CTSL | |
| SCHEMBL6896682 | 0.87 | HSD17B10 (0.42) | CHRM1HSD17B10ALDH1A1CYP3A4CTSL | |
| SCHEMBL28747238 | 0.87 | HSD17B10 (0.44) | CHRM1HSD17B10ALDH1A1CTSLKDM4E | |
| SCHEMBL6895008 | 0.87 | HSD17B10 (0.42) | CHRM1HSD17B10ALDH1A1CYP3A4CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | CHRM1 340/4885HSD17B10 1909/4885ALDH1A1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.